HUE049305T2 - Pirazolo[1,5-a]pirazin-4-il származékok mint JAK-inhibitorok - Google Patents

Pirazolo[1,5-a]pirazin-4-il származékok mint JAK-inhibitorok

Info

Publication number: HUE049305T2
Authority: HU; Hungary
Prior art keywords: jak; pyrazin; pyrazolo; inhibitors; derivatives
Prior art date: 2016-02-24

Application number

HUE17705705A

Other languages

English (en)

Inventor

Matthew Frank Brown

Alpay DERMENCI

Andrew Fensome

Brian Stephen Gerstenberger

Matthew Merrill Hayward

Dafydd Rhys Owen

Stephen Wayne Wright

Li Huang Xing

Xiaojing Yang

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-24

Filing date

2017-02-10

Publication date

2020-09-28

2017-02-10 Application filed by Pfizer filed Critical Pfizer

2020-09-28 Publication of HUE049305T2 publication Critical patent/HUE049305T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)

HUE17705705A 2016-02-24 2017-02-10 Pirazolo[1,5-a]pirazin-4-il származékok mint JAK-inhibitorok HUE049305T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662299130P	2016-02-24	2016-02-24

Publications (1)

Publication Number	Publication Date
HUE049305T2 true HUE049305T2 (hu)	2020-09-28

Family

ID=58054385

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE17705705A HUE049305T2 (hu)	2016-02-24	2017-02-10	Pirazolo[1,5-a]pirazin-4-il származékok mint JAK-inhibitorok

Country Status (45)

Country	Link
US (4)	US10144738B2 (hu)
EP (2)	EP3712153B1 (hu)
JP (1)	JP6505956B2 (hu)
KR (1)	KR102128671B1 (hu)
CN (1)	CN109071546B (hu)
AR (1)	AR107714A1 (hu)
AU (1)	AU2017222417B2 (hu)
CA (1)	CA2958490C (hu)
CL (1)	CL2018002358A1 (hu)
CO (1)	CO2018008799A2 (hu)
CR (1)	CR20180372A (hu)
CU (1)	CU24511B1 (hu)
CY (1)	CY1122949T1 (hu)
DK (1)	DK3419978T3 (hu)
DO (1)	DOP2018000187A (hu)
EA (1)	EA035036B1 (hu)
EC (1)	ECSP18072109A (hu)
ES (1)	ES2794779T3 (hu)
GE (1)	GEP20217242B (hu)
HK (1)	HK1258157A1 (hu)
HR (1)	HRP20200781T1 (hu)
HU (1)	HUE049305T2 (hu)
IL (1)	IL260923B (hu)
LT (1)	LT3419978T (hu)
MA (2)	MA43668B1 (hu)
MD (1)	MD3419978T2 (hu)
ME (1)	ME03743B (hu)
MX (1)	MX2018010236A (hu)
MY (1)	MY189118A (hu)
NI (1)	NI201800080A (hu)
NZ (1)	NZ744349A (hu)
PH (1)	PH12018501788A1 (hu)
PL (1)	PL3419978T3 (hu)
PT (1)	PT3419978T (hu)
RS (1)	RS60261B1 (hu)
RU (1)	RU2718902C2 (hu)
SG (1)	SG11201806307YA (hu)
SI (1)	SI3419978T1 (hu)
SV (1)	SV2018005726A (hu)
TN (1)	TN2018000295A1 (hu)
TW (1)	TWI665201B (hu)
UA (1)	UA119835C2 (hu)
UY (1)	UY37133A (hu)
WO (1)	WO2017144995A1 (hu)
ZA (1)	ZA201804972B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE049305T2 (hu)	2016-02-24	2020-09-28	Pfizer	Pirazolo[1,5-a]pirazin-4-il származékok mint JAK-inhibitorok
JP7474709B2 (ja)	2018-02-27	2024-04-25	インサイト・コーポレイション	Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
UY38144A (es) *	2018-03-12	2019-10-31	Abbvie Inc	Inhibidores de la señalización mediada por tirosina cinasa
CR20200554A (es)	2018-05-17	2021-01-12	Bayer Ag	Derivados sustituidos de la carboxamida dihidropirazolo pirazina
MA52940A (fr)	2018-05-18	2021-04-28	Incyte Corp	Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
AU2019297361B2 (en)	2018-07-05	2024-06-27	Incyte Corporation	Fused pyrazine derivatives as A2A / A2B inhibitors
TW202033198A (zh)	2018-10-17	2020-09-16	美商美國禮來大藥廠	以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
JP7256291B2 (ja) *	2019-04-12	2023-04-11	プライムジーン（ベイジン）カンパニーリミテッド	ピラゾロピラジン誘導の化合物、医薬組成物およびその使用
SG11202112043PA (en)	2019-04-30	2021-11-29	Celgene Corp	Combination therapies comprising apremilast and tyk2 inhibitors
AU2020347561A1 (en) *	2019-09-11	2022-04-14	Pfizer Inc.	Treatment of hidradenitis with JAK inhibitors
TW202135816A (zh) *	2019-12-18	2021-10-01	美商輝瑞股份有限公司	以激酶抑制劑治療潰瘍性結腸炎
CA3177852A1 (en)	2020-04-04	2021-10-07	Pfizer Inc.	Methods of treating coronavirus disease 2019
WO2021205322A1 (en) *	2020-04-08	2021-10-14	Pfizer Inc.	Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
AU2021339756A1 (en) *	2020-09-11	2023-04-13	Pulmosim Therapeutics Llc	Compositions and methods for treating or preventing pulmonary hypertension
CN112592345B (zh) *	2020-12-07	2024-09-13	嘉兴特科罗生物科技有限公司	一种三氮唑并吡嗪类化合物及其用途
US20240174662A1 (en) *	2021-02-01	2024-05-30	Janssen Biotech, Inc.	Small molecule inhibitors of salt inducible kinases
KR20230152087A (ko)	2021-03-30	2023-11-02	화이자 인코포레이티드	백반증을 치료하는 방법
EP4423086A1 (en)	2021-10-25	2024-09-04	Kymera Therapeutics, Inc.	Tyk2 degraders and uses thereof
CA3237632A1 (en) *	2021-11-12	2023-05-19	Changqing WEI	Pyrazolo fused ring compound and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2672172C (en)	2006-12-22	2016-05-03	Astex Therapeutics Limited	Bicyclic heterocyclic compounds as fgfr inhibitors
AR066879A1 (es) *	2007-06-08	2009-09-16	Novartis Ag	Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP2299821B1 (en)	2008-06-10	2015-11-04	AbbVie Inc.	Tricyclic compounds
US8518952B2 (en)	2008-08-06	2013-08-27	Pfizer Inc.	6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors
US8927545B2 (en)	2009-03-30	2015-01-06	Duke University	Inhibiting Eph B-3 kinase
UY33213A (es) *	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
KR20130094710A (ko) *	2010-04-14	2013-08-26	어레이 바이오파마 인크.	Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
EP2397482A1 (en)	2010-06-15	2011-12-21	Almirall, S.A.	Heteroaryl imidazolone derivatives as jak inhibitors
JP2014528475A (ja) *	2011-10-12	2014-10-27	アレイバイオファーマ、インコーポレイテッド	５，７置換イミダゾ［１，２−ｃ］ピリミジン
US9187453B2 (en) *	2012-03-28	2015-11-17	Takeda Pharmaceutical Company Limited	Heterocyclic compound
AU2013242492B2 (en)	2012-03-28	2016-12-15	Merck Patent Gmbh	Bicyclic pyrazinone derivatives
BR112016001954A2 (pt)	2013-07-31	2017-08-01	Gilead Sciences Inc	composto, composição farmacêutica, e, método para tratar uma doença ou condição
TW201605811A (zh)	2013-12-11	2016-02-16	阿爾米雷爾有限公司	作為jak抑制劑之吡唑并嘧啶-2基衍生物
EP3137454A1 (en) *	2014-04-28	2017-03-08	Pfizer Inc.	Heteroaromatic compounds and their use as dopamine d1 ligands
WO2016009028A1 (fr)	2014-07-17	2016-01-21	Valeo Systèmes d'Essuyage	Balai plat caréné d'essuie-glace
MX2017007284A (es) *	2014-12-05	2017-08-25	Array Biopharma Inc	Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas.
TW201639845A (zh)	2015-01-29	2016-11-16	和記黃埔醫藥（上海）有限公司	新的雜芳基和雜環化合物、其組成物及方法
CN113563342A (zh)	2015-02-13	2021-10-29	达纳－法伯癌症研究所公司	Lrrk2抑制剂及其制备和使用方法
GB201504565D0 (en)	2015-03-18	2015-05-06	Takeda Pharmaceutical	Novel compounds
MX370933B (es)	2015-04-29	2020-01-09	Wuxi Fortune Pharmaceuticals Co Ltd	Inhibidores jak.
WO2017108723A2 (en)	2015-12-22	2017-06-29	F. Hoffmann-La Roche Ag	PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
HUE049305T2 (hu)	2016-02-24	2020-09-28	Pfizer	Pirazolo[1,5-a]pirazin-4-il származékok mint JAK-inhibitorok
CA3047580A1 (en)	2016-12-23	2018-07-26	Plexxikon Inc.	Compounds and methods for cdk8 modulation and indications therefor
ES2948194T3 (es)	2017-01-18	2023-09-01	Array Biopharma Inc	Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
WO2018234342A1 (en)	2017-06-21	2018-12-27	F. Hoffmann-La Roche Ag	ISOINDOLINONE DERIVATIVES AS MODULATORS OF IRAK4
WO2019034973A1 (en)	2017-08-14	2019-02-21	Pfizer Inc.	PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES

2017
- 2017-02-10 HU HUE17705705A patent/HUE049305T2/hu unknown
- 2017-02-10 EP EP20168877.7A patent/EP3712153B1/en active Active
- 2017-02-10 MA MA43668A patent/MA43668B1/fr unknown
- 2017-02-10 DK DK17705705.6T patent/DK3419978T3/da active
- 2017-02-10 CU CU2018000078A patent/CU24511B1/es unknown
- 2017-02-10 MA MA052987A patent/MA52987A/fr unknown
- 2017-02-10 CR CR20180372A patent/CR20180372A/es unknown
- 2017-02-10 PT PT177057056T patent/PT3419978T/pt unknown
- 2017-02-10 AU AU2017222417A patent/AU2017222417B2/en active Active
- 2017-02-10 RU RU2018130547A patent/RU2718902C2/ru active
- 2017-02-10 NZ NZ744349A patent/NZ744349A/en unknown
- 2017-02-10 EA EA201891463A patent/EA035036B1/ru unknown
- 2017-02-10 SG SG11201806307YA patent/SG11201806307YA/en unknown
- 2017-02-10 PL PL17705705T patent/PL3419978T3/pl unknown
- 2017-02-10 SI SI201730289T patent/SI3419978T1/sl unknown
- 2017-02-10 LT LTEP17705705.6T patent/LT3419978T/lt unknown
- 2017-02-10 MD MDE20190031T patent/MD3419978T2/ro unknown
- 2017-02-10 UA UAA201808148A patent/UA119835C2/uk unknown
- 2017-02-10 GE GEAP201714864A patent/GEP20217242B/en unknown
- 2017-02-10 JP JP2018544300A patent/JP6505956B2/ja active Active
- 2017-02-10 KR KR1020187024431A patent/KR102128671B1/ko active IP Right Grant
- 2017-02-10 MX MX2018010236A patent/MX2018010236A/es unknown
- 2017-02-10 TN TNP/2018/000295A patent/TN2018000295A1/en unknown
- 2017-02-10 RS RS20200584A patent/RS60261B1/sr unknown
- 2017-02-10 MY MYPI2018702937A patent/MY189118A/en unknown
- 2017-02-10 CN CN201780013165.4A patent/CN109071546B/zh active Active
- 2017-02-10 ME MEP-2020-97A patent/ME03743B/me unknown
- 2017-02-10 CO CONC2018/0008799A patent/CO2018008799A2/es unknown
- 2017-02-10 WO PCT/IB2017/050748 patent/WO2017144995A1/en active Application Filing
- 2017-02-10 EP EP17705705.6A patent/EP3419978B1/en active Active
- 2017-02-10 ES ES17705705T patent/ES2794779T3/es active Active
- 2017-02-21 CA CA2958490A patent/CA2958490C/en active Active
- 2017-02-21 TW TW106105777A patent/TWI665201B/zh active
- 2017-02-21 US US15/437,618 patent/US10144738B2/en active Active
- 2017-02-22 UY UY0001037133A patent/UY37133A/es unknown
- 2017-02-23 AR ARP170100462A patent/AR107714A1/es active IP Right Grant
2018
- 2018-07-18 SV SV2018005726A patent/SV2018005726A/es unknown
- 2018-07-24 ZA ZA2018/04972A patent/ZA201804972B/en unknown
- 2018-08-01 IL IL260923A patent/IL260923B/en unknown
- 2018-08-03 NI NI201800080A patent/NI201800080A/es unknown
- 2018-08-17 CL CL2018002358A patent/CL2018002358A1/es unknown
- 2018-08-23 PH PH12018501788A patent/PH12018501788A1/en unknown
- 2018-08-24 DO DO2018000187A patent/DOP2018000187A/es unknown
- 2018-09-24 EC ECSENADI201872109A patent/ECSP18072109A/es unknown
- 2018-11-06 US US16/181,596 patent/US10822341B2/en active Active
2019
- 2019-01-14 HK HK19100512.8A patent/HK1258157A1/zh unknown
2020
- 2020-05-13 HR HRP20200781TT patent/HRP20200781T1/hr unknown
- 2020-05-15 CY CY20201100470T patent/CY1122949T1/el unknown
- 2020-09-08 US US17/014,533 patent/US11472809B2/en active Active
2022
- 2022-09-07 US US17/939,375 patent/US12129256B2/en active Active

Also Published As

Publication number	Publication date
CN109071546A (zh)	2018-12-21
RU2018130547A (ru)	2020-03-25
SV2018005726A (es)	2018-10-24
MY189118A (en)	2022-01-26
UA119835C2 (uk)	2019-08-12
CU24511B1 (es)	2021-05-12
US20190071448A1 (en)	2019-03-07
NZ744349A (en)	2023-06-30
ZA201804972B (en)	2019-06-26
BR112018015501A2 (pt)	2018-12-18
EP3419978B1 (en)	2020-04-15
KR20180103158A (ko)	2018-09-18
RS60261B1 (sr)	2020-06-30
SI3419978T1 (sl)	2020-08-31
NI201800080A (es)	2018-11-22
LT3419978T (lt)	2020-06-10
AU2017222417A1 (en)	2018-08-02
GEP20217242B (en)	2021-04-12
MX2018010236A (es)	2019-01-14
US20230045252A1 (en)	2023-02-09
MD3419978T2 (ro)	2020-07-31
TW201741313A (zh)	2017-12-01
EP3712153A1 (en)	2020-09-23
CR20180372A (es)	2018-09-19
SG11201806307YA (en)	2018-09-27
JP2019510003A (ja)	2019-04-11
MA43668B1 (fr)	2020-05-29
EP3712153B1 (en)	2021-12-01
MA52987A (fr)	2021-04-28
CA2958490A1 (en)	2017-08-24
CO2018008799A2 (es)	2018-09-20
US20170240552A1 (en)	2017-08-24
CY1122949T1 (el)	2021-10-29
DOP2018000187A (es)	2019-01-31
AR107714A1 (es)	2018-05-23
KR102128671B1 (ko)	2020-06-30
JP6505956B2 (ja)	2019-04-24
CN109071546B (zh)	2021-03-02
EP3419978A1 (en)	2019-01-02
PH12018501788A1 (en)	2019-06-17
EA035036B1 (ru)	2020-04-20
RU2018130547A3 (hu)	2020-03-25
AU2017222417B2 (en)	2020-07-09
ME03743B (me)	2021-04-20
US11472809B2 (en)	2022-10-18
UY37133A (es)	2017-09-29
EA201891463A1 (ru)	2019-03-29
US20200399281A1 (en)	2020-12-24
CA2958490C (en)	2024-02-27
US10144738B2 (en)	2018-12-04
ES2794779T3 (es)	2020-11-19
PT3419978T (pt)	2020-06-01
IL260923B (en)	2022-01-01
US10822341B2 (en)	2020-11-03
RU2718902C2 (ru)	2020-04-15
ECSP18072109A (es)	2018-10-31
CU20180078A7 (es)	2019-02-04
CL2018002358A1 (es)	2018-11-30
HK1258157A1 (zh)	2019-11-08
PL3419978T3 (pl)	2020-11-30
WO2017144995A1 (en)	2017-08-31
US12129256B2 (en)	2024-10-29
TWI665201B (zh)	2019-07-11
DK3419978T3 (da)	2020-06-02
HRP20200781T1 (hr)	2020-07-24
TN2018000295A1 (en)	2020-01-16

Publication	Publication Date	Title
HK1258157A1 (zh)	2019-11-08	作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物
HRP20211261T8 (hr)	2022-01-21	[1,2,4]triazolo[1,5-a]piridinil supstituirani spojevi indola
ZA201905456B (en)	2021-09-29	Pyrrolo[1,2-b]pyridazine derivatives
HK1256751A1 (zh)	2019-10-04	[1，2，4]三唑並[1，5-a]嘧啶-7-基化合物
IL266305B (en)	2021-10-31	History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
IL254224A0 (en)	2017-10-31	7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
EP3280715A4 (en)	2019-03-13	NOVEL 5 OR 8 SUBSTITUTED IMIDAZO [1,5-A] PYRIDINS AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES
ZA201902562B (en)	2022-12-21	Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides
HK1254809A1 (zh)	2019-07-26	治療中有用的吡唑並[1，5-a]三嗪-4-胺衍生物
ZA201605666B (en)	2021-01-27	Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL262673A (en)	2018-12-31	A pyrazolo[5,1-a]pyrimidine compound
IL290419B (en)	2022-10-01	Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL272988A (en)	2020-04-30	Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
HK1257427A1 (zh)	2019-10-18	用於製備2-吡唑並[1，5-a]吡嗪-2-基吡啶並[1，2-a]嘧啶-4-酮的方法